The same stock keeps hitting the same level. We keep following it.

What the system saw

Four times in nine days. That's not a typo — that's the Relative Strength Engine doing exactly what it's built to do. CRNX sits in the 96th percentile of relative strength over the past 63 trading days, and it keeps coming back to the same level: the 20-day moving average. It keeps holding. Every time it does, the system raises its hand. So here we are again.

Why our Relative Strength Engine liked it

The logic isn't complicated: stocks outperforming nearly everything else in the market don't usually stop without a reason. Right now, CRNX is sitting just 0.82% above its 20-day moving average at $83.92 — essentially kissing support. Today's low was $84.36. It hasn't cracked. Volume dried up on the pullback, which is exactly what you want to see if buyers are still in control. The Relative Strength Engine scored this one 71/100, with the bulk of the points coming from that RS rank and the clean hold at the moving average. Now, the fundamentals deserve an honest look: this is a biotech with a negative P/E, negative EBITDA, and an EPS trend moving in the wrong direction. ROE sits at -44%. Analyst consensus is Buy, with an average target of $84.86 — which is almost exactly where we're entering. The Altman Z-Score is an unusually high 39.4, suggesting no near-term financial distress, but the Piotroski F-Score is 2/9, meaning the underlying business quality is weak. We're not buying the company. We're following price action in a technically strong name — and we're managing risk tightly because of exactly that fundamental picture.

The trade plan

The Relative Strength Engine entered at $84.61 with a stop at $83.53 — $1.08 of risk per share. Our system's target sits at $86.79, right at 2R. We're putting $4,992 behind this one: 59 shares. The stop sits below today's low and below the 20-day moving average, so if CRNX loses that level, we're out. Simple as that. One more thing worth flagging: this brings us to five open CRNX positions across different entry dates, all sitting in various states of small gains or flat. The paper account manages each one individually — every position lives and dies by its own stop.

Position size: our paper account is putting about $4,992 (59 shares) into this trade, sized to risk roughly $64 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

The most obvious risk here is concentration. If CRNX flushes through $83.53, multiple positions take a hit at once — and we're not going to pretend that isn't a real exposure. The fundamentals aren't providing a safety net either: negative margins, negative returns on capital, and a DCF that spits out a negative fair value. There's no fundamental floor under this one. This trade is entirely technical, and if the price action breaks down, it breaks down on its own. The overall system's win rate sits at 0% through 10 closed trades, with the account up 1.3% against SPY's 3.5% over the same 29-day window. What's keeping the book afloat are the open positions — SNOW at +24.5% and CORT at +20.2% — and we're watching both of those carefully.

One more thought before we go

The question we keep asking is whether four signals on the same name in nine days means the system is working — or the system is being stubborn. The answer probably depends on what happens next. CRNX either holds this moving average and runs, or it doesn't, and we find out whether the setup was as clean as it looked.